基因组分类器预测前列腺切除术后PSA持续患者转移
多中心研究纳入477例根治性前列腺切除术患者,其中150例术后PSA可检测(≥0.1 ng/ml)。在多变量分析中,基因组高风险(HR 5.95)、PSA可检测(HR 4.26)和淋巴结侵犯(HR 12.2)为转移的独立预后因素;PSA可检测患者中基因组高风险者5年转移率为18% vs 低/中风险0.90%。
要点
- 术后PSA可检测患者中,基因组高风险是转移的独立预后因素(HR 5.61)。
- PSA可检测患者5年转移率:基因组高风险18% vs 低/中风险0.90%(p<0.001)。
- 基因组分类器联合CAPRA-S或Gandaglia的C-index为0.82或0.81。
核心结论
- 尽管PSA可检测患者具有更高侵袭性临床病理特征,Decipher仍独立预测转移。
- 需要前瞻性验证,将在正在进行的随机试验NRG GU-002中收集。
研究设计与样本
- 多中心研究纳入1990至2015年间在三家学术中心接受根治性前列腺切除术的477例患者。
- 根据术后PSA最低值≥0.1 ng/ml将患者分为PSA可检测组(n=150)和不可检测组(n=327)。
主要发现
- 中位随访(删失患者)57个月,从根治性前列腺切除术至首次术后PSA的中位时间1.4个月。
- 多变量分析中,基因组高风险(HR 5.95,95%CI 2.02-19.41,p=0.001)、PSA可检测(HR 4.26,95%CI 1.16-21.8,p=0.03)和淋巴结侵犯(HR 12.2,95%CI 2.46-70.7,p=0.003)为转移的预后因素。
- PSA可检测患者中,基因组低/中风险的5年转移率为0.90%,基因组高风险为18%(p<0.001)。
- PSA可检测患者中,基因组高风险在多变量分析中仍为独立预后因素(HR 5.61,95%CI 1.48-22.7,p=0.01)。
- CAPRA-S评分、Gandaglia列线图以及基因组分类器联合CAPRA-S或Gandaglia的C-index分别为0.69、0.68、0.82或0.81。
临床怎么用
- 对于根治性前列腺切除术后PSA可检测的患者,可考虑使用Decipher基因组分类器进行风险分层。
局限性
- 样本量是一个局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer patients who have a detectable prostate-specific antigen (PSA) postprostatectomy may harbor pre-existing metastatic disease. To our knowledge, none of the commercially available genomic biomarkers have been investigated in such men. OBJECTIVE: To evaluate if a 22-gene genomic classifier can independently predict development of metastasis in men with PSA persistence postoperatively. DESIGN, SETTING, AND PARTICIPANTS: A multi-institutional study of 477 men who underwent radical prostatectomy (RP) between 1990 and 2015 from three academic centers. Patients were categorized as detectable PSA (n=150) or undetectable (n=327) based on post-RP PSA nadir ≥0.1 ng/ml. OUTCOME MEASUREMENTS AND STATISITICAL ANALYSIS: Cumulative incidence curves for metastasis were constructed using Fine-Gray competing risks analysis. Penalized Cox univariable and multivariable (MVA) proportional hazards models were performed to evaluate the association of the genomic classifier with metastasis. RESULTS AND LIMITATIONS: The median follow-up for censored patients was 57 mo. The median time from RP to first postoperative PSA was 1.4 mo. Detectable PSA patients were more likely to have higher adverse pathologic features compared with undetectable PSA patients. On MVA, only genomic high-risk (hazard ratio [HR]: 5.95, 95% confidence interval [CI]: 2.02-19.41, p=0.001), detectable PSA (HR: 4.26, 95% CI: 1.16-21.8, p=0.03), and lymph node invasion (HR: 12.2, 95% CI: 2.46-70.7, p=0.003) remained prognostic factors for metastasis. Among detectable PSA patients, the 5-yr metastasis rate was 0.90% for genomic low/intermediate and 18% for genomic high risk (p<0.001). Genomic high risk remained independently prognostic on MVA (HR: 5.61, 95% CI: 1.48-22.7, p=0.01) among detectable PSA patients. C-index for Cancer of the Prostate Risk Assessment Postsurgical score, Gandaglia nomogram, and the genomic classifier plus either Cancer of the Prostate Risk Assessment Postsurgical score or Gandaglia were 0.69, 0.68, and 0.82 or 0.81, respectively. Sample size was a limitation. CONCLUSIONS: Despite patients with a detectable PSA harboring significantly higher rates of aggressive clinicopathologic features, Decipher independently predicts for metastasis. Prospective validation of these findings is warranted and will be collected as part of the ongoing randomized trial NRG GU-002. PATIENT SUMMARY: Decipher independently predicted metastasis for patients with detectable prostate-specific antigen after prostatectomy.
引用
- Spratt DE, Dai DLY, Den RB, et al. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Eur Urol. 2017. PMID: 29233664. doi:10.1016/j.eururo.2017.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。